DE69432627T2 - Polymergebundene camptothecin-derivate - Google Patents

Polymergebundene camptothecin-derivate Download PDF

Info

Publication number
DE69432627T2
DE69432627T2 DE69432627T DE69432627T DE69432627T2 DE 69432627 T2 DE69432627 T2 DE 69432627T2 DE 69432627 T DE69432627 T DE 69432627T DE 69432627 T DE69432627 T DE 69432627T DE 69432627 T2 DE69432627 T2 DE 69432627T2
Authority
DE
Germany
Prior art keywords
phe
formula
leu
gly
camptothecin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69432627T
Other languages
German (de)
English (en)
Other versions
DE69432627D1 (en
Inventor
Francesco Angelucci
Antonino Suarato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia Italia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia SpA filed Critical Pharmacia Italia SpA
Application granted granted Critical
Publication of DE69432627D1 publication Critical patent/DE69432627D1/de
Publication of DE69432627T2 publication Critical patent/DE69432627T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE69432627T 1993-10-08 1994-09-21 Polymergebundene camptothecin-derivate Expired - Fee Related DE69432627T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939320781A GB9320781D0 (en) 1993-10-08 1993-10-08 Polymer-bound camptothecin derivatives
GB9320781 1993-10-08
PCT/EP1994/003154 WO1995010304A1 (en) 1993-10-08 1994-09-21 Polymer-bound camptothecin derivatives

Publications (2)

Publication Number Publication Date
DE69432627D1 DE69432627D1 (en) 2003-06-12
DE69432627T2 true DE69432627T2 (de) 2004-03-25

Family

ID=10743226

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432627T Expired - Fee Related DE69432627T2 (de) 1993-10-08 1994-09-21 Polymergebundene camptothecin-derivate

Country Status (24)

Country Link
US (1) US5773522A (cg-RX-API-DMAC7.html)
EP (1) EP0673258B1 (cg-RX-API-DMAC7.html)
JP (1) JPH08504217A (cg-RX-API-DMAC7.html)
KR (1) KR100359005B1 (cg-RX-API-DMAC7.html)
CN (1) CN1138565C (cg-RX-API-DMAC7.html)
AT (1) ATE239507T1 (cg-RX-API-DMAC7.html)
AU (1) AU679788B2 (cg-RX-API-DMAC7.html)
CA (1) CA2150132A1 (cg-RX-API-DMAC7.html)
DE (1) DE69432627T2 (cg-RX-API-DMAC7.html)
DK (1) DK0673258T3 (cg-RX-API-DMAC7.html)
ES (1) ES2198421T3 (cg-RX-API-DMAC7.html)
FI (1) FI952746A7 (cg-RX-API-DMAC7.html)
GB (1) GB9320781D0 (cg-RX-API-DMAC7.html)
HU (1) HU215588B (cg-RX-API-DMAC7.html)
IL (1) IL111173A (cg-RX-API-DMAC7.html)
MY (1) MY116624A (cg-RX-API-DMAC7.html)
NZ (1) NZ273952A (cg-RX-API-DMAC7.html)
PL (1) PL178132B1 (cg-RX-API-DMAC7.html)
PT (1) PT673258E (cg-RX-API-DMAC7.html)
RU (1) RU2149646C1 (cg-RX-API-DMAC7.html)
TW (1) TW316905B (cg-RX-API-DMAC7.html)
UA (1) UA42706C2 (cg-RX-API-DMAC7.html)
WO (1) WO1995010304A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA947823B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
WO1998014459A1 (de) * 1996-09-30 1998-04-09 Bayer Aktiengesellschaft Glycokonjugate von modifizierten camptothecin-derivaten (20-o-verknüpfung)
DE19640969A1 (de) * 1996-10-04 1998-04-16 Bayer Ag 20-0-verknüpfte Glycokonjugate von Camptothecin
ID23424A (id) * 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
GB9721069D0 (en) * 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
GB9721070D0 (en) * 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Bioactive derivatives of camptothecin
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
GB9915180D0 (en) * 1999-06-29 1999-09-01 Pharmacia & Upjohn Spa Antitumour compound
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
AU1820400A (en) * 1999-11-17 2001-05-30 School Of Pharmacy, University Of London, The Conjugates of hpma copolymer and ellipticin
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
GB0008928D0 (en) * 2000-04-11 2000-05-31 Pharmacia & Upjohn Spa A method of administering an antitumour compound
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
WO2003033525A1 (en) * 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
US6933302B2 (en) 2002-06-03 2005-08-23 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
ITPD20050242A1 (it) * 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
US7875602B2 (en) 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN101265331B (zh) * 2007-03-12 2010-10-13 中国科学院化学研究所 Peg改性phpma材料及其制备方法
WO2011150022A2 (en) 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
EP3574922B1 (en) * 2013-04-10 2021-09-15 Syndevrx, Inc. Modified or polymer-conjugated fumagillol metap2 inhibitors for use in improving or restoring insulin sensitivity
JP6529130B2 (ja) * 2013-08-26 2019-06-12 国立研究開発法人科学技術振興機構 接着剤
KR102849342B1 (ko) 2015-12-10 2025-08-21 신데브알엑스, 인크. 푸마길롤 유도체 및 그의 다형체
AU2017206718B2 (en) 2016-01-11 2021-09-30 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
US11612577B2 (en) 2018-10-26 2023-03-28 Syndevrx, Inc. Biomarkers of METAP2 inhibitors and applications thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
GB9309663D0 (en) * 1993-05-11 1993-06-23 Erba Carlo Spa Biologically active compounds

Also Published As

Publication number Publication date
AU679788B2 (en) 1997-07-10
EP0673258B1 (en) 2003-05-07
NZ273952A (en) 1996-10-28
FI952746A0 (fi) 1995-06-05
CN1138565C (zh) 2004-02-18
ATE239507T1 (de) 2003-05-15
CA2150132A1 (en) 1995-04-20
MY116624A (en) 2004-03-31
IL111173A (en) 1998-10-30
PL309328A1 (en) 1995-10-02
KR100359005B1 (ko) 2003-04-26
ES2198421T3 (es) 2004-02-01
UA42706C2 (uk) 2001-11-15
GB9320781D0 (en) 1993-12-01
TW316905B (cg-RX-API-DMAC7.html) 1997-10-01
DK0673258T3 (da) 2003-08-25
CN1115564A (zh) 1996-01-24
PT673258E (pt) 2003-09-30
WO1995010304A1 (en) 1995-04-20
ZA947823B (en) 1995-07-03
HU9502084D0 (en) 1995-09-28
IL111173A0 (en) 1994-12-29
HU215588B (hu) 1999-01-28
US5773522A (en) 1998-06-30
FI952746A7 (fi) 1995-06-05
AU7783694A (en) 1995-05-04
HUT71678A (en) 1996-01-29
JPH08504217A (ja) 1996-05-07
DE69432627D1 (en) 2003-06-12
RU2149646C1 (ru) 2000-05-27
RU95112841A (ru) 1997-06-27
EP0673258A1 (en) 1995-09-27
PL178132B1 (pl) 2000-03-31

Similar Documents

Publication Publication Date Title
DE69821783T2 (de) Polymere verbindungen von camptothecin
US5773522A (en) Polymer-bound camptothecin derivatives
DE69730352T2 (de) Verfahren zur herstellung eines arzneimittelkomplexes
EP0939765B1 (de) Glycokonjugate von modifizierten camptothecin-derivaten(a- oder b-ring-verknüpfung)
DE69734607T2 (de) Langwirkende arzneistoffe und diese enthaltende arzneimittel
DE69730332T2 (de) Alkyldextran-polyalcohol Arzneimittel-Komplexe
DE69429689T2 (de) Durch lysosomale Enzyme spaltbare Antitumor-Wirkstoff-Konjugate
DE60223499T2 (de) Terminal verzweigte, polymere linker und diese enthaltende polymere konjugate
EP0819135B1 (de) Kohlenhydratmodifizierte cytostatika
EP0934329B1 (de) Glycokonjugate von modifizierten camptothecin-derivaten (20-o-verknüpfung)
DE60223496T2 (de) Endgruppenverzweigte polymere verbindungsgruppen und diese enthaltende polymere konjugate
EP0981542B1 (de) Glycokonjugate von 20(s)-camptothecin
EP0929570A1 (de) Modifizierte cytostatika
DE69427799T2 (de) Anthracycline konjugate, deren herstellung und deren verwendung als antitumorwirkstoffe
CN110152013B (zh) 一种果胶-阿霉素轭合物及其制备方法和用途
DE69532578T2 (de) NEUARTIGE GnRH - ANALOGE MIT ANTITUMORALEN EFFEKTEN UND SIE ENTHALTENDE PHARMAZEUTISCHE ZUBEREITUNGEN
CN110418653B (zh) 一种果胶-阿霉素轭合物及其制备方法和用途
WO2001058932A1 (de) Glycokonjugate von cytostatika
DE10005275A9 (de) Neuartige glycokonjugate
WO1998015573A1 (de) 20-o-verknüpfte glycokonjugate von camptothecin
DE19813137A1 (de) Glycokonjugate von 20(S)-Camptothecin
DD296485A5 (de) Verfahren zur herstellung von taxolderivaten
DE19801037A1 (de) Glycokonjugate von 20(S)-Camptothecin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee